<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81667">
  <stage>Registered</stage>
  <submitdate>30/10/2006</submitdate>
  <approvaldate>31/10/2006</approvaldate>
  <actrnumber>ACTRN12606000457549</actrnumber>
  <trial_identification>
    <studytitle>A randomised, double blind, placebo controlled, parallel trial of folic acid and the improvement of endothelial dysfunction in obese children and adolescents</studytitle>
    <scientifictitle>Effects of folic acid on endothelial function in obese children and adolescents</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Children, Youth and Women's Health Service (CYWHS) Ethics Committee: REC 1513</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obese children and adolescents</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>5 mg oral folic acid taken daily for 8 weeks</interventions>
    <comparator>Placebo tablets taken orally once a day for 8 weeks. Placebo tablets contain: Lactose  (58.842 mg), Cellulose (6.538 mg), Hydrogenated Vegetable Oil  (2.100 mg), Magnesium Stearate  (0.350 mg), Quinoline Yellow Lake (2.009 mg), Sunset Yellow Lake (0.154 mg), Brilliant Blue Lake (0.007 mg)</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Endothelial function measured by flow mediated dilatation</outcome>
      <timepoint>At -8, 0, 8 and 16 weeks. Two measurements pre and 2 measurements post treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Folate and homocysteine levels</outcome>
      <timepoint>Also measured at -8, 0, 8 and 16 weeks.Two measurements pre and two measurements post treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Glyceryl trinitrate mediated dilatation</outcome>
      <timepoint>Also measured at -8, 0, 8 and 16 weeks.Two measurements pre and two measurements post treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Obese children.</inclusivecriteria>
    <inclusiveminage>10</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Current or recent use of Vitamin B or folic acid supplements, metformin, orlistat, Angiotensin Converting Enzyme inhibitiors, HMGCoA reductase inhibitors, and/or antihyoertensive treatment. Vitamin B12 deficiency. Smoking. Hypertension. Type 2 diabetes according to World Health Organization criteria. Endocrinological or syndromal causes of obesity.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment was done by pharmacy using numbered containers</concealment>
    <sequence>Simple randomisation using Fisher table from a statistic book.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Subjects and Assessor</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>2/01/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Children, Youth and Women's Health Service</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Women's and Chidlren's Research Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>IPRS and University of Adelaide Scholarship</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Adelaide</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Worldwide obesity has increased over the last decade. Paediatric obesity is known to be an independent risk factor for adult obesity. Adolescent obesity is associated with atherosclerosis. Atherosclerosis is preceded by endothelial or blood vessel dysfunction that can be assessed by ultrasound. Endothelial dysfunction occurs in severely obese children. Early interventions to improve endothelial dysfunction in obesity, in addition to metabolic and weight control may potentially prevent atherosclerosis and heart disease. Folic acid has been proposed as one of the strategies to reduce atherosclerosis and hasn't been investigated in obesity.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Children, Youth and Women's Health Service</ethicname>
      <ethicaddress />
      <ethicapprovaldate>21/11/2003</ethicapprovaldate>
      <hrec>1513/10/2006</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jennifer Couper</name>
      <address>C/O Endocrine Department
Children, Youth and Women's Health Service
72 King William Road
North Adelaide SA 5006</address>
      <phone>+61 8 81616402</phone>
      <fax>+61 8 81617759</fax>
      <email>jennifer.couper@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Alexia Sophie Pe√±a</name>
      <address>C/O Endocrine Department
Children, Youth and Women's Health Service
72 King William Road
North Adelaide SA 5006</address>
      <phone>+61 8 81616402</phone>
      <fax>+61 8 81617759</fax>
      <email>alexia.pena@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>